, Les émissions de CO2 liées à la consommation de carburants sont moins taxées que dans la plupart des autres pays
, Graphique 22.1. Les femmes ont généralement une espérance de vie plus longue que les hommes, mais leur espérance de vie en bonne santé est équivalente
, UN AUTRE REGARD SUR LE CHANGEMENT, Le mouvement de l'être, pp.143-154, 2011.
Commentary on and reprint of Nowell PC, Hungerford DA, A minute chromosome in human chronic granulocytic leukemia, in Science (1960) 132:1497, Hematology, vol.132, pp.513-515, 2000. ,
Acellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia, Nature, vol.300, pp.765-772, 1982. ,
Chronic myeloid leukemia from basics to bedside, Leukemia, vol.13, issue.11, pp.1646-1674, 1999. ,
Leucémie myéloïde chronique, EMC - Hématologie, vol.2, issue.3, pp.187-205, 2005. ,
The molecular biology of chronic myeloid leukemia, Blood, vol.96, issue.10, pp.3343-3356, 2000. ,
Crkl is constitutively tyrosine phosphorylated in platelets from chronic myelogenous leukemia patients and inducibly phosphorylated in normal platelets stimulated by thrombopoietin, Blood, vol.88, issue.11, pp.4304-4313, 1996. ,
Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway, The EMBO Journal, vol.16, issue.20, pp.6151-6161, 1997. ,
STAT5 Activation by BCR-Abl Contributes to Transformation of K562 Leukemia Cells, Blood, vol.94, issue.3, pp.1108-1112, 1999. ,
Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway, Genes & Development, vol.12, issue.10, pp.1415-1424, 1998. ,
Deep Molecular Response in Chronic Myeloid Leukemia: The New Goal of Therapy?, Clinical Cancer Research, vol.20, issue.2, pp.310-322, 2013. ,
Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia, New England Journal of Medicine, vol.348, issue.11, pp.994-1004, 2003. ,
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia, New England Journal of Medicine, vol.355, issue.23, pp.2408-2417, 2006. ,
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia, N Engl J Med, vol.355, pp.2408-2425, 2006. ,
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia, Leukemia, vol.23, issue.6, pp.1054-1061, 2009. ,
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia, New England Journal of Medicine, vol.376, issue.10, pp.917-927, 2017. ,
Survival advantage from imatinib compared with the combination interferon-? plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials, Blood, vol.108, issue.5, pp.1478-1484, 2006. ,
Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis, Journal of Clinical Oncology, vol.26, issue.20, pp.3358-3363, 2008. ,
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV, Leukemia, vol.29, issue.5, pp.1123-1132, 2015. ,
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial, Journal of Clinical Oncology, vol.34, issue.20, pp.2333-2340, 2016. ,
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial, Leukemia, vol.30, issue.5, pp.1044-1054, 2016. ,
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial, Leukemia, vol.30, pp.1044-1054, 2016. ,
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial, Journal of Clinical Oncology, vol.36, issue.3, pp.231-237, 2018. ,
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial, Journal of Clinical Oncology, vol.36, issue.3, pp.231-237, 2018. ,
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome?Positive Leukemias, New England Journal of Medicine, vol.369, issue.19, pp.1783-1796, 2013. ,
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial, The Lancet Oncology, vol.17, issue.5, pp.612-621, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01812697
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS), Blood, vol.116, issue.19, pp.3758-3765, 2010. ,
Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib, Blood, vol.120, issue.2, pp.291-294, 2012. ,
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML), Leukemia, vol.26, issue.9, pp.2096-2102, 2012. ,
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study, Blood, vol.111, issue.8, pp.4022-4028, 2008. ,
Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia, Blood, vol.112, issue.5, pp.2024-2027, 2008. ,
The Functional Activity of the OCT-1 Protein Is Predictive of Molecular Response and Survival in CP-CML Patients Treated with Imatinib: A 5 Year Update of the TIDEL Trial., Blood, vol.114, issue.22, pp.507-507, 2009. ,
Ibrahim AR, Eliasson L, Apperley JF, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 2011;117(14):3733?3736., Blood, vol.120, issue.24, pp.4903-4903, 2012. ,
Discontinuation of imatinib therapy after achieving a molecular response, Blood, vol.104, issue.7, pp.2204-2205, 2004. ,
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years, Blood, vol.109, issue.1, pp.58-60, 2006. ,
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial, The Lancet Oncology, vol.11, issue.11, pp.1029-1035, 2010. ,
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia, Journal of Clinical Oncology, vol.35, issue.3, pp.298-305, 2017. ,
Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease, Journal of Clinical Oncology, vol.32, issue.5, pp.424-430, 2014. ,
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study, Blood, vol.122, issue.4, pp.515-522, 2013. ,
Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study, Haematologica, vol.101, issue.6, pp.717-723, 2016. ,
Stopping tyrosine kinaseinhibitors in a very large cohort of European chronicmyeloid leukemia patients: Results of the EURO-SKItrial. 21st EHA Congress, Haematologica, vol.101, p.145, 2016. ,
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial, The Lancet Oncology, vol.19, issue.6, pp.747-757, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01859932
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study, Blood, vol.129, issue.7, pp.846-854, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-02050833
,
Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop, Blood, vol.128, issue.22, pp.792-792, 2016. ,
PF411 ENESTOP 192-WK RESULTS: DURABILITY AND IMPACT ON QUALITY OF LIFE OF TREATMENT-FREE REMISSION (TFR) FOLLOWING SECOND-LINE (2L) NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML), HemaSphere, vol.3, issue.S1, p.158, 2019. ,
Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study Ann Intern Med, vol.168, pp.461-470, 2018. ,
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study, Journal of Cancer Research and Clinical Oncology, vol.144, issue.5, pp.945-954, 2018. ,
Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan, Haematologica, vol.103, issue.11, pp.1835-1842, 2018. ,
Discontinuation of Nilotinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Deep Molecular Responses for at Least 2 Years: A Multicenter Phase 2 Stop Nilotinib (Nilst) Trial, Blood, vol.128, issue.22, pp.790-790, 2016. ,
Treatment-free remission (TFR) in patients with chronic phase chronic myeloid leukemia (CML-CP) and in stable deep molecular response (DMR) to dasatinib -the DASFREE Study, Blood, vol.128, 2016. ,
Discontinuation of Dasatinib after Deep Molecular Response for over 2 Years in Patients with Chronic Myelogenous Leukemia and the Unique Profiles of Lymphocyte Subsets for Successful Discontinuation: A Prospective, Multicenter Japanese Trial (D-STOP Trial), Blood, vol.128, issue.22, pp.791-791, 2016. ,
Pharmacokinetics of Dasatinib as a First Line Therapy In Newly Diagnosed CML Patients (OPTIM dasatinib trial): Correlation with Safety and Response., Blood, vol.116, issue.21, pp.3432-3432, 2010. ,
Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial, The Lancet Haematology, vol.2, issue.12, pp.e528-e535, 2015. ,
Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment, Clinical Lymphoma Myeloma and Leukemia, vol.18, issue.5, pp.353-360.e1, 2018. ,
De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial, The Lancet Haematology, vol.6, issue.7, pp.e375-e383, 2019. ,
Final results of the DESTINY study of de-escalation and stopping treatment in chronic myeloid leukemia, Haematologica, vol.809, 2018. ,
Second Attempt of TKI Discontinuation with Dasatinib for Treatment-Free Remission after Failing First Attempt with Imatinib: Treatment-Free Remission Accomplished By Dasatinib (TRAD), Trial Blood, vol.132, p.787, 2018. ,
Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia, Cancer, vol.123, issue.22, pp.4403-4410, 2017. ,
Lymphocytes NK : un rôle majeur dans le contrôle immunologique de la leucémie myéloïde chronique, médecine/sciences, vol.34, issue.6-7, pp.540-546, 2018. ,
Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study, Haematologica, vol.102, issue.8, pp.1368-1377, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-02043232
CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors, Blood, vol.129, issue.9, pp.1166-1176, 2017. ,
Novel tyrosine-kinase inhibitors for the treatment of chronic myeloid leukemia: safety and efficacy, Expert Review of Hematology, vol.11, issue.4, pp.301-306, 2018. ,